Cargando…

Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain

BACKGROUND: (18)F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of (18)F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Kok Pin, Pascoal, Tharick A., Mathotaarachchi, Sulantha, Therriault, Joseph, Kang, Min Su, Shin, Monica, Guiot, Marie-Christine, Guo, Qi, Harada, Ryuichi, Comley, Robert A., Massarweh, Gassan, Soucy, Jean-Paul, Okamura, Nobuyuki, Gauthier, Serge, Rosa-Neto, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374697/
https://www.ncbi.nlm.nih.gov/pubmed/28359327
http://dx.doi.org/10.1186/s13195-017-0253-y
_version_ 1782518945613348864
author Ng, Kok Pin
Pascoal, Tharick A.
Mathotaarachchi, Sulantha
Therriault, Joseph
Kang, Min Su
Shin, Monica
Guiot, Marie-Christine
Guo, Qi
Harada, Ryuichi
Comley, Robert A.
Massarweh, Gassan
Soucy, Jean-Paul
Okamura, Nobuyuki
Gauthier, Serge
Rosa-Neto, Pedro
author_facet Ng, Kok Pin
Pascoal, Tharick A.
Mathotaarachchi, Sulantha
Therriault, Joseph
Kang, Min Su
Shin, Monica
Guiot, Marie-Christine
Guo, Qi
Harada, Ryuichi
Comley, Robert A.
Massarweh, Gassan
Soucy, Jean-Paul
Okamura, Nobuyuki
Gauthier, Serge
Rosa-Neto, Pedro
author_sort Ng, Kok Pin
collection PubMed
description BACKGROUND: (18)F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of (18)F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on (18)F-THK5351 brain uptake using PET and autoradiography. METHODS: Eight participants (five mild cognitive impairment, two Alzheimer’s disease, and one progressive supranuclear palsy) had baseline (18)F-AZD4694 and (18)F-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second (18)F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third (18)F-THK5351 scan 9–28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after (18)F-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. (18)F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline. RESULTS: At baseline, (18)F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced (18)F-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9–28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on (18)F-THK5351 uptake. CONCLUSIONS: These results indicate that the interpretation of (18)F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of (18)F-THK5351 scans using reference region methods.
format Online
Article
Text
id pubmed-5374697
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53746972017-04-03 Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain Ng, Kok Pin Pascoal, Tharick A. Mathotaarachchi, Sulantha Therriault, Joseph Kang, Min Su Shin, Monica Guiot, Marie-Christine Guo, Qi Harada, Ryuichi Comley, Robert A. Massarweh, Gassan Soucy, Jean-Paul Okamura, Nobuyuki Gauthier, Serge Rosa-Neto, Pedro Alzheimers Res Ther Research BACKGROUND: (18)F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of (18)F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on (18)F-THK5351 brain uptake using PET and autoradiography. METHODS: Eight participants (five mild cognitive impairment, two Alzheimer’s disease, and one progressive supranuclear palsy) had baseline (18)F-AZD4694 and (18)F-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second (18)F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third (18)F-THK5351 scan 9–28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after (18)F-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. (18)F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline. RESULTS: At baseline, (18)F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced (18)F-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9–28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on (18)F-THK5351 uptake. CONCLUSIONS: These results indicate that the interpretation of (18)F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of (18)F-THK5351 scans using reference region methods. BioMed Central 2017-03-31 /pmc/articles/PMC5374697/ /pubmed/28359327 http://dx.doi.org/10.1186/s13195-017-0253-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ng, Kok Pin
Pascoal, Tharick A.
Mathotaarachchi, Sulantha
Therriault, Joseph
Kang, Min Su
Shin, Monica
Guiot, Marie-Christine
Guo, Qi
Harada, Ryuichi
Comley, Robert A.
Massarweh, Gassan
Soucy, Jean-Paul
Okamura, Nobuyuki
Gauthier, Serge
Rosa-Neto, Pedro
Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
title Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
title_full Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
title_fullStr Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
title_full_unstemmed Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
title_short Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
title_sort monoamine oxidase b inhibitor, selegiline, reduces (18)f-thk5351 uptake in the human brain
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374697/
https://www.ncbi.nlm.nih.gov/pubmed/28359327
http://dx.doi.org/10.1186/s13195-017-0253-y
work_keys_str_mv AT ngkokpin monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT pascoaltharicka monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT mathotaarachchisulantha monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT therriaultjoseph monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT kangminsu monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT shinmonica monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT guiotmariechristine monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT guoqi monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT haradaryuichi monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT comleyroberta monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT massarwehgassan monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT soucyjeanpaul monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT okamuranobuyuki monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT gauthierserge monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain
AT rosanetopedro monoamineoxidasebinhibitorselegilinereduces18fthk5351uptakeinthehumanbrain